Educational reference, not medical advice. This page summarizes information from published research and regulatory filings for educational purposes. It is not a recommendation to use any compound and should not replace guidance from a licensed healthcare provider. Most peptides discussed here are not approved for the uses described.
What it is
Pentadeca Arginate, abbreviated PDA, is an arginate-salt formulation of the 15-amino-acid sequence found in BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). The peptide is the same; the counterion is arginine rather than the acetate form found in conventional BPC-157 preparations.
The arginate counterion is described by suppliers as conferring improved stability in solution and a longer effective half-life. Published peer-reviewed evidence supporting these claims for this specific salt form is limited.
History
PDA emerged commercially in late 2023 — directly after the FDA placed BPC-157 in Category 2 of its 503A bulk substances list, effectively prohibiting US compounding pharmacies from preparing it. The arginate salt form had not been a commercial product before that date. The marketing position has been that PDA is a chemically distinct entity not covered by the BPC-157 restriction, though the active peptide sequence is identical.
Regulatory status
There is no separate FDA review or approval of Pentadeca Arginate. The compound is sold through research peptide suppliers labeled for non-human research use. Compounding pharmacies that previously prepared BPC-157 may or may not be preparing the arginate form depending on their interpretation of the 503A restriction; the legal status of PDA in compounding contexts is ambiguous.
How researchers describe its action
Mechanistic claims for PDA are extrapolations from the BPC-157 literature, since the active sequence is the same. Those mechanism papers describe modulation of nitric oxide signaling, VEGFR2 upregulation, and growth hormone receptor expression in tendon — all in preclinical rodent studies.
No published paper describes the pharmacokinetics or biological activity of the arginate-salt form specifically. The marketing assertion that it is more stable in solution is plausible chemistry (arginine counterions can buffer pH and stabilize certain peptides) but has not been documented for this sequence.
Half-life and dosing intervals
The half-life of the underlying BPC-157 sequence is short — roughly 15 to 30 minutes after subcutaneous injection. The arginate salt is marketed with claims of a longer duration of action; no pharmacokinetic study confirming this has been published.
Observational protocols described in research channels typically use doses similar to BPC-157 (200–500 mcg once or twice daily). These are extrapolations from animal data, not established human doses.
Reconstitution example
PDA vials are typically 5 mg or 10 mg of lyophilized powder. A 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL — the same math as BPC-157.
What to know
- Very limited evidence specific to the arginate form. Most claims rely on the BPC-157 literature, where the active sequence is identical.
- Regulatory ambiguity. PDA's market existence is largely a response to the BPC-157 compounding restriction; the regulatory durability of this distinction is uncertain.
- Same precautions as BPC-157 apply: research-only, not approved, no Phase II safety data.
- Storage. Refrigerate lyophilized vials; refrigerate reconstituted solution and use within the stability window provided by the supplier.